Posted On: 01/19/2016 11:46:52 PM
Post# of 72443
NR keeps comparing Trius' tedizolid, a newer version of an existing class of antibiotics where cross-resistance is likely, not to mention it's once a day for six days, to Brilacidin. We all know which one is superior, so there's no comparison.
Quote:
He's figuring that the entire defensin mimetic platform will be worth 750 Million AFTER B positive P3 results.
(0)
(0)
Scroll down for more posts ▼
